1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor

TNF Receptor (肿瘤坏死因子)

Tumor Necrosis Factor Receptor; TNFR

肿瘤坏死因子 (TNF) 是细胞凋亡以及炎症和免疫的主要介质,并且与多种人类疾病的发病机制有关,包括败血症、糖尿病、癌症、骨质疏松症、多发性硬化症、类风湿性关节炎和炎症性肠病。

TNF-α 是一种 17 kDa 蛋白质,由 157 个氨基酸组成,在溶液中为同源三聚体。在人类中,该基因位于 6 号染色体上。其生物活性主要受可溶性 TNF-α 结合受体的调节。TNF-α 主要由活化的巨噬细胞、T 淋巴细胞和自然杀伤细胞产生。已知多种其他细胞的表达较低,包括成纤维细胞、平滑肌细胞和肿瘤细胞。在细胞中,TNF-α 合成为 pro-TNF (26 kDa),它与膜结合,在 TNF 转换酶 (TACE) 裂解其 pro 结构域后释放。

许多 TNF 诱导的细胞反应是由两种 TNF 受体 TNF-R1 和 TNF-R2 中的任一种介导的,这两种受体都属于 TNF 受体超家族。在 TNF 治疗后,转录因子 NF-κB 和 MAP 激酶(包括 ERK、p38 和 JNK)在大多数类型的细胞中被激活,在某些情况下,也可能诱导细胞凋亡或坏死。然而,诱导细胞凋亡或坏死主要是通过 TNFR1 实现的,TNFR1 也称为死亡受体。NF-κB 和 MAPK 的激活在多种细胞因子和免疫调节蛋白的诱导中起着重要作用,并且对许多炎症反应至关重要。

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99775
    Placulumab

    普拉鲁单抗

    Inhibitor
    Placulumab (ART621) 是一种抗 TNF α 单克隆抗体。Placulumab 具有抗炎活性,在关节炎等炎性疾病中有潜在应用。
    Placulumab
  • HY-164894
    ABBV-3373 Inhibitor 98.78%
    ABBV-3373 是一种抗 TNF 的抗体-药物偶联物 (ADC)。ABBV-3373 是由人源化 TNF 抗体 Adalimumab (HY-P9908) 和糖皮质激素受体激动剂 (HY-148436) 连接组成。ABBV-3373 可用于类风湿关节炎的研究。
    ABBV-3373
  • HY-117082
    UTL-5g Inhibitor 99.92%
    UTL-5g (GBL-5g) 是一种抗炎性 TNF-α 抑制剂,具有化学保护和肝脏放射保护作用。UTL-5g 通过抑制 TNF-α 等因子降低顺铂引起的肝毒性、肾毒性和骨髓毒性。
    UTL-5g
  • HY-N8884
    Coelonin Inhibitor ≥98.0%
    Coelonin 是一种具有抗炎活性的二氢菲。Coelonin 可抑制 LPS 诱导的 PTEN 磷酸化。Coelonin 通过负向调节 PI3K/AKT 通路抑制 NF-κB 激活和 p27Kip1 降解。Coelonin 可抑制 IκBα 的磷酸化和降解,增加 IκBα 蛋白的表达。
    Coelonin
  • HY-P10551
    ApoA-I mimetic peptide 5A Inhibitor
    ApoA-I mimetic peptide 5A 是一种合成的肽类分子,根据天然存在的载脂蛋白A-I (Apo A-I) 的结构和功能设计的。ApoA-I mimetic peptide 5A 能够促进胆固醇从细胞内向外流出,有助于减少细胞内胆固醇的积累。ApoA-I mimetic peptide 5A 还显示出抗炎活性,能够降低血液和组织中的炎症标志物。ApoA-I mimetic peptide 5A 可用于心血管疾病的研究。
    ApoA-I mimetic peptide 5A
  • HY-N0262R
    Cordycepin (Standard)

    虫草素 (Standard)

    Cordycepin (Standard) 是 Cordycepin 的分析标准品。本产品用于研究及分析应用。Cordycepin (3'-Deoxyadenosine) 是一种核苷衍生物,在类风湿性关节炎滑膜成纤维细胞 (RASF) 中,抑制 IL-1β 诱导的 MMP-1MMP-3 表达,这种作用存在剂量依赖性。Cordycepin 通过抑制细菌的腺苷激酶杀死结核分枝杆菌。
    Cordycepin (Standard)
  • HY-B0026
    Ceftiofur hydrochloride

    头孢噻呋盐酸盐

    Inhibitor 98.43%
    Ceftiofur hydrochloride 是一种靶向细菌青霉素结合蛋白 (PBPs) 的细胞壁合成抑制剂,在内毒素血症中具有抗炎作用。Ceftiofur hydrochloride 通过抑制细菌细胞壁肽聚糖的合成发挥杀菌作用,导致细菌细胞裂解。Ceftiofur hydrochloride 还抑制 NF-κBMAPKs 的激活,从而减少 TNF-α、IL-1β 和 IL-6 等促炎细胞因子的分泌。
    Ceftiofur hydrochloride
  • HY-P3203A
    DSTYSLSSTLTLSK TFA 98.11%
    DSTYSLSSTLTLSK TFA 是人通用肽,可用于英夫利昔单抗定量检测。 Infliximab (Avakine) 是一种嵌合的单克隆 IgG1 抗体,特异性结合到 TNF-α。
    DSTYSLSSTLTLSK TFA
  • HY-147086
    CAY10789 Inhibitor 99.84%
    CAY10789 是一种有效的 CysLT1R 拮抗剂 (IC50=2.80 μM) 和 GPBAR1 激动剂 (EC50=3 μM)。CAY10789 显著降低 U937 细胞对 HAEC 的粘附,降低 TNF-α 的表达。CAY10789 具有良好的代谢稳定性和良好的药代动力学。 CAY10789 可用于结肠炎、代谢综合征等 GPBAR1/CysLT1R 相关疾病的研究。
    CAY10789
  • HY-N0182A
    Fisetin quarterhydrate

    漆黄素

    Inhibitor 98.64%
    Fisetin quarterhydrate是一种在许多水果和蔬菜中发现的天然黄酮醇,具有多种益处,如抗氧化,抗癌,神经保护作用。
    Fisetin quarterhydrate
  • HY-N0569R
    Madecassic acid (Standard)

    羟基积雪草酸(标准品)

    Inhibitor
    Madecassic acid (Standard) 是 Madecassic acid 的分析标准品。本产品用于研究及分析应用。Madecassic acid 分离自积雪草(伞形科)。Madecassic acid 具有 iNOSCOX-2TNF-αIL-1betaIL-6 抑制作用,可通过在 RAW 264.7 巨噬细胞中下调 NF-κB 激活而具有抗炎作用。
    Madecassic acid (Standard)
  • HY-121892
    (Z)-KC02
    (Z)-KC02 是一种 ABHD16A 抑制剂,ABHD16A 是产生溶血-PS 的磷脂酰丝氨酸 (PS) 脂肪酶。溶血磷脂酰丝氨酸 (lyso-PS) 是一种信号脂,调节免疫和神经过程。它与多种神经系统疾病,如色素性视网膜炎和白内障 (PHARC) 有关。(Z)-KC02 可以消耗 PHARC 受试者的淋巴母细胞中的 lyso-PS。(Z)-KC02 还减少巨噬细胞中 lyso-PS 和脂多糖诱导的细胞因子的产生,调节体内 lyso-PS 代谢。
    (Z)-KC02
  • HY-101170
    BU224 hydrochloride Inhibitor
    BU224 hydrochloride 是一种选择性高亲和力的咪唑啉 imidazoline I2 受体配体,Ki 为 2.1 nM。BU224 hydrochloride 有时被用作 I2 受体拮抗剂。BU224 hydrochloride 具有神经保护作用,具有抗炎、抗凋亡作用。BU224 hydrochloride 可改善 5XFAD 小鼠的记忆,增大树突棘和减少 Aβ 诱导的 NMDARs 的变化。BU224 hydrochloride 可用于阿尔茨海默病研究。
    BU224 hydrochloride
  • HY-N0619A
    cis-Mulberroside A Inhibitor
    cis-Mulberroside A (Mulberroside D) 是 Mulberroside A 的顺式异构体。Mulberroside A 是桑树 (Morus alba L.) 中的主要生物活性成分之一。Mulberroside A 可降低 TNF-αIL-1βIL-6 的表达,抑制 NALP3,caspase-1NF-κB 的激活以及 ERKJNK 和 p38 的磷酸化 。Mulberroside A 具有抗炎和抗细胞凋亡作用。Mulberroside A 对蘑菇酪氨酸酶 ( tyrosinase) 具有抑制活性,IC50 为 53.6 μM。
    cis-Mulberroside A
  • HY-12085S
    Apremilast-d5

    阿普司特 d5

    Inhibitor 99.26%
    Apremilast-d5 是一种 Apremilast 氘代物。Apremilast (CC-10004) 是一种口服有效的磷酸二酯酶 4 (PDE4) 抑制剂,IC50 为 74 nM。Apremilast 抑制脂多糖 (LPS) 释放 TNF-α,IC50 为 104 nM。
    Apremilast-d<sub>5</sub>
  • HY-100376
    CPI-1189 Inhibitor 98.49%
    CPI-1189 是一种具有口服活性的 TNF-α 释放抑制剂。CPI-1189 可抑制 p38 的磷酸化。CPI-1189 能抑制细胞凋亡 (apoptosis)。CPI-1189 可用于 HIV 和神经系统疾病的研究。
    CPI-1189
  • HY-159884
    MG-T-19 Activator
    MG-T-19 是有效的 TIM-3 抑制剂,能抑制 TIM-3PtdSerCEACAM1Gal-9 的相互作用。MG-T-19 能增加来自健康供体的外周血单个核细胞 (PBMCs) 的肿瘤坏死因子-α (TNF-α) 和干扰素-γ (IFN-γ) 的产生,并增强 PBMCs 抑制 Kasumi-1 细胞 (急性髓系白血病细胞系) 增殖的能力。
    MG-T-19
  • HY-W010201R
    Citronellol (Standard)

    香茅醇 (标准品);

    Modulator
    Citronellol (Standard) 是 Citronellol (HY-W010201) 的分析标准品。Citronellol (Standard) 是一种口服有效的凋亡 (apoptosis) 诱导剂。Citronellol (Standard) 可以通过调节 ROS-NOMAPK/ERKPI3K/Akt 信号通路预防 6-OHDA 诱导的 SH-SY5Y 细胞帕金森病模型中的氧化应激、线粒体功能障碍和凋亡。Citronellol (Standard) 可以通过 TNF-α 途径和活性氧 (ROS) 积累诱导人肺癌细胞坏死性凋亡 (necroptosis)。Citronellol (Standard) 可以降低 LC-3p62 水平来调节自噬 (autophagy) 途径,抑制氧化应激和神经炎症,从而对帕金森大鼠具有神经保护作用。Citronellol (Standard) 通过抑制麦角甾醇合成从而对红色毛癣菌具有抗真菌 (fungal) 活性。
    Citronellol (Standard)
  • HY-P99669
    Iratumumab

    伊妥木单抗

    Inhibitor 98.95%
    Iratumumab (MDX-060) 是一种人抗 CD30 的 IgG1κ 单克隆抗体。Iratumumab 抑制表达 CD30 的肿瘤细胞的生长。 Iratumumab 可用于霍奇金淋巴瘤 (HL) 和间变性大细胞淋巴瘤 (ALCL) 的研究。
    Iratumumab
  • HY-160178
    Glucocorticoid receptor agonist-3 Ala-Ala-Mal Inhibitor 99.72%
    Glucocorticoid receptor agonist-3 Ala-Ala-Mal (化合物 Preparation 8) 是一种抗人 TNFα 抗体-糖皮质激素受体 (glucocorticoid receptor) 激动剂 (GC) 缀合物。Glucocorticoid receptor agonist-3 Ala-Ala-Mal 可用于自身免疫性疾病和炎性疾病的研究。
    Glucocorticoid receptor agonist-3 Ala-Ala-Mal
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival. 

 

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis. 

 

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].

 

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 
 

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.